Q3 2014 13F Holders as of 9/30/2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
89M
-
Shares change
-
+3.25M
-
Total reported value, excl. options
-
$810M
-
Value change
-
+$28.6M
-
Put/Call ratio
-
0.88
-
Number of buys
-
58
-
Number of sells
-
-56
-
Price
-
$9.10
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2014
153 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2014.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89M shares
of 124M outstanding shares and own 71.94% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.8M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (6.94M shares), BB Biotech AG (6.43M shares), VANGUARD GROUP INC (6.26M shares), Sectoral Asset Management Inc (4.56M shares), QVT Financial LP (4.06M shares), BlackRock Fund Advisors (3.76M shares), First Eagle Investment Management, LLC (3.64M shares), State Street Corp (3.27M shares), and FMR LLC (3.21M shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.